BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 26831162)

  • 1. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
    Reimann MJ; Ljungvall I; Hillström A; Møller JE; Hagman R; Falk T; Höglund K; Häggström J; Olsen LH
    Vet J; 2016 Mar; 209():113-8. PubMed ID: 26831162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
    J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
    J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of serum cardiac troponin I and acute phase protein concentrations with clinical staging in dogs with degenerative mitral valve disease.
    Polizopoulou ZS; Koutinas CK; Cerón JJ; Tvarijonaviciute A; Martínez-Subiela S; Dasopoulou A; York MJ; Roman IF; Gandhi M; Patel S; O'Brien PJ
    Vet Clin Pathol; 2015 Sep; 44(3):397-404. PubMed ID: 26288324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
    J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating cytokine concentrations in dogs with different degrees of myxomatous mitral valve disease.
    Zois NE; Moesgaard SG; Kjelgaard-Hansen M; Rasmussen CE; Falk T; Fossing C; Häggström J; Pedersen HD; Olsen LH
    Vet J; 2012 Apr; 192(1):106-11. PubMed ID: 21696985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
    Cremer SE; Kristensen AT; Reimann MJ; Eriksen NB; Petersen SF; Marschner CB; Tarnow I; Oyama MA; Olsen LH
    Am J Vet Res; 2015 Jun; 76(6):520-31. PubMed ID: 26000599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
    Lee CM; Jeong DM; Kang MH; Kim SG; Han JI; Park HM
    Am J Vet Res; 2017 Apr; 78(4):440-446. PubMed ID: 28345991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs.
    Ljungvall I; Höglund K; Tidholm A; Olsen LH; Borgarelli M; Venge P; Häggström J
    J Vet Intern Med; 2010; 24(1):153-9. PubMed ID: 20002554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
    J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
    Morgan KRS; Monteith G; Raheb S; Colpitts M; Fonfara S
    Vet J; 2020 Sep; 263():105518. PubMed ID: 32928487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and its association with oxidative stress in dogs with heart failure.
    Nemec Svete A; Verk B; Čebulj-Kadunc N; Salobir J; Rezar V; Domanjko Petrič A
    BMC Vet Res; 2021 Apr; 17(1):176. PubMed ID: 33902566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue Doppler and strain imaging in dogs with myxomatous mitral valve disease in different stages of congestive heart failure.
    Tidholm A; Ljungvall I; Höglund K; Westling AB; Häggström J
    J Vet Intern Med; 2009; 23(6):1197-207. PubMed ID: 19909428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease.
    Vereb M; Atkins CE; Adin D; Blondel T; Coffman M; Lee S; Guillot E; Ward JL
    J Vet Intern Med; 2024; 38(1):51-60. PubMed ID: 37909399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum serotonin concentration is associated with severity of myxomatous mitral valve disease in dogs.
    Ljungvall I; Höglund K; Lilliehöök I; Oyama MA; Tidholm A; Tvedten H; Häggström J
    J Vet Intern Med; 2013; 27(5):1105-12. PubMed ID: 23865457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
    BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
    J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.